
Opinion|Videos|February 28, 2026
Considerations for integrating immunotherapy into earlier stages of bladder cancer
Author(s)Kristen R. Scarpato, MD, MPH
Fact checked by: Hannah Clarke
Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer.
Advertisement
In the following video, Kristen R. Scarpato, MD, MPH, discusses the potential role of emerging immunotherapy-based combinations in the treatment of BCG-naive, high-risk non–muscle invasive bladder cancer (NMIBC). Scarpato is an associate professor of urology at Vanderbilt University Medical Center in Nashville, Tennessee.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves enfortumab vedotin plus pembrolizumab for MIBC
2
Study suggests tamsulosin deprescribing may be appropriate for select men with BPH
3
Amy E. Krambeck, MD, on choosing between CVAC and FANS for suction-based ureteroscopy
4
Trial launches of actinium (225Ac) rhPSMA-10.1 injection in mCRPC
5













